MOXO-Mobile: the first Attention Deficit Hyperactive Disorder (ADHD) screening mobile application, using Eye Tracking and Continuous Performance Test components to give the first evidence of attention

Projektinformationen

MOXO-Mobile Phase-1

ID Finanzhilfevereinbarung: 877041

DOI

10.3030/877041

Projekt abgeschlossen

EK-Unterschriftsdatum 25 Juli 2019

Startdatum 1 August 2019

Enddatum 31 Januar 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

NEURO TECHNOLOGY SOLUTIONS LTD
Israel

Periodic Reporting for period 1 - MOXO-Mobile Phase-1 (MOXO-Mobile: the first Attention Deficit Hyperactive Disorder (ADHD) screening mobile application, using Eye Tracking and Continuous Performance Test components to give the first evidence of attention)

Berichtszeitraum: 2019-08-01 bis 2020-01-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Living with undiagnosed ADHD (Attention Deficit Hyperactive Disorder) cause severe learning, social and health difficulties, affecting various aspects of life at any age, early diagnosis can dramatically change that. The need for accessible, objective, early ADHD screening is imperative- and such a solution does not exist today. SeeMe Mobile (previously called MOXO-Mobile) is the first-ever Scientifically-Objective, self-assessment application for screening ADHD, which combines the accuracy of working with biomarkers and measurable data while democratizing accessibility by offering the solution as an appealing and entertained mobile application for smartphones.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The App utilizes Eye Tracking (ET) and CPT (Continuous Performance Test) data, to characterize the user’s attentional profile, providing initial evidence of attention difficulties, evaluating ADHD probability, and suggesting follow-up steps. During the present project, we conducted a pilot with our desktop version product (SeeMe) in order to learn about the commercialization channels needed for a B2C product, and the costs required. Moreover, we validated the eye tracking parameters collected during our attentional test as distinguishing between ADHD and control subjects.
In order to examine the business feasibility of the product, the company conducted a wide market research which included a desk research, focus groups, and one-on-one interviews with clinicians and key personals in UK.
In our study, we learned that parents to children with ADHD, or in the process of diagnosis, spend considerable time waiting due to 1-2 years waiting list at the NHS, to understand their child’s condition, without any practical tools for helping them cope.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Therefore we concluded, that in order to minimize the waiting time for diagnosis, Neurotech Solutions will address the NHS, and offer SeeMe Mobile as a screening tool for the General Practitioners (GP) as well as a prioritizing tool for the pediatricians, making SeeMe Mobile a B2B2C product. The company will plan a pilot study with a group of NHS GPs and pediatricians in order to prove the cost effectiveness of SeeMe Mobile in the process of ADHD diagnosis in UK. The pilot will focus on contribution to the screening process at schools, the prioritizing process between the GPs and the specialists, and on the improvement of quality of life of those in the process.

More information: https://www.neurotech-solutions.com/

neurotech-team.jpg